

Attorney Docket No.: **ISPH-0518**  
Inventors: **Baker et al.**  
Serial No.: **09/695,451**  
Filing Date: **October 24, 2000**  
Page 4

**REMARKS**

Claims 1, 2, and 5-15 are pending in this application. Reconsideration is respectfully requested in view of the following remarks.


At the outset, Applicants thank Examiner Schultz for the courtesy of a telephone interview on February 9, 2004. In Applicants' response to the original restriction requirement, claim 1 was amended to recite SEQ ID NO:1 as the target sequence. In response to the Office Action mailed 7/16/03, Applicants amended the claims to recite regions of the target sequence, i.e., nucleobases 727-868 and 899-1310 of SEQ ID NO:1.

The Notice of Non-Responsive Amendment indicates that the limitation to these target regions within SEQ ID NO:1 was not responsive. However, following the telephone interview, it was agreed that these two regions could be searched. Accordingly, Applicants elect an antisense compound 8 to 30 nucleobases in length targeted to nucleobases 727 through 868 or nucleobases 899.

Attorney Docket No.: ISPH-0518  
Inventors: Baker et al.  
Serial No.: 09/695,451  
Filing Date: October 24, 2000  
Page 5

through 1310 of a nucleic acid molecule encoding TNFR1 (SEQ ID NO:1), wherein said compound specifically inhibits the expression of TNFR1.

Respectfully submitted,



Jane Massey Licata  
Registration No. 32,257

Date: February 10, 2004

Licata & Tyrrell P.C.  
66 Main Street  
Marlton, NJ 08053

856-810-1515